Status:
COMPLETED
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Kentuckiana Cancer Institute
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
Detailed Description
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
- Karnofsky score 60% or greater
- patients who will be treated with Gemcitabine
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00283478
Start Date
May 1 2004
End Date
April 1 2007
Last Update
October 31 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kentuckiana Cancer Institute
Louisville, Kentucky, United States, 40202